The association between circulating endostatin levels and incident myocardial infarction

References

• O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277–285.
   PubMed Web of Science ®Google Scholar
• Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev. 2009;28:177–183.
   PubMed Web of Science ®Google Scholar
• Tian HL, Chen H, Cui YH, et al. Increased protein and mRNA expression of endostatin in the ischemic brain tissue of rabbits after middle cerebral artery occlusion. Neurosci Bull. 2007;23:35–40.
   PubMedGoogle Scholar
• Hou Q, Ling L, Wang F, et al. Endostatin expression in neurons during the early stage of cerebral ischemia is associated with neuronal apoptotic cell death in adult hypertensive rat model of stroke. Brain Res. 2010;1311:182–188.
   PubMed Web of Science ®Google Scholar
• Mitsuma W, Kodama M, Hanawa H, et al. Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Cardiol. 2007;99:494–498.
   PubMed Web of Science ®Google Scholar
• Iribarren C, Herrinton LJ, Darbinian JA, et al. Does the association between serum endostatin, an endogenous anti-angiogenic protein, and acute myocardial infarction differ by race?. Vasc Med. 2006;11:13–20.
   PubMed Web of Science ®Google Scholar
• Liou JY, Shyu KG, Lu MJ, et al. Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease. J Formos Med Assoc. 2006;105:377–383.
   PubMed Web of Science ®Google Scholar
• Arnlov J, Ruge T, Ingelsson E, et al. Serum endostatin and risk of mortality in the elderly: findings from 2 community-based cohorts. Arterioscler Thromb Vasc Biol. 2013;33:2689–2695.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Holmgren L, Janlert U, et al. Large improvements in major cardiovascular risk factors in the population of northern Sweden: the MONICA study 1986–2009. J Intern Med. 2011;269:219–231.
   PubMed Web of Science ®Google Scholar
• Norberg M, Wall S, Boman K, et al. The Vasterbotten Intervention Programme: background, design and implications. Glob Health Action 2010;3:4643.
   PubMed Web of Science ®Google Scholar
• Lukanova A, Bjor O, Kaaks R, et al. Body mass index and cancer: results from the Northern Sweden Health and Disease Cohort. Int J Cancer. 2006;118:458–466.
   PubMed Web of Science ®Google Scholar
• Norberg M, Blomstedt Y, Lonnberg G, et al. Community participation and sustainability - evidence over 25 years in the Vasterbotten Intervention Programme. Glob Health Action. 2012;5:19166.
   PubMed Web of Science ®Google Scholar
• Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891–897.
   PubMed Web of Science ®Google Scholar
• Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898–904.
   PubMed Web of Science ®Google Scholar
• Seko Y, Fukuda S, Nagai R. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy. Clin Sci. 2004;106:439–442.
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Somaratne JB, Jenkins AJ, et al. Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. Int J Cardiol. 2013;167:1027–1037.
   PubMedGoogle Scholar
• Pearce WH, Shively VP. Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann N Y Acad Sci. 2006;1085:117–132.
   PubMed Web of Science ®Google Scholar
• Abou-Raya S, Naim A, Marzouk S. Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clin Invest Med. 2004;27:93–100.
   PubMed Web of Science ®Google Scholar
• Shami A, Goncalves I, Hultgardh-Nilsson A. Collagen and related extracellular matrix proteins in atherosclerotic plaque development. Curr Opin Lipidol. 2014;25:394–399.
   PubMed Web of Science ®Google Scholar
• Oka T, Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J. 2008;72:A13–A16.
   PubMedGoogle Scholar
• Isobe K, Kuba K, Maejima Y, et al. Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circ J. 2010;74:109–119.
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 1999;13:9–22.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298–307.
   PubMed Web of Science ®Google Scholar
• Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054–2061.
   PubMed Web of Science ®Google Scholar
• Sodha NR, Boodhwani M, Clements RT, et al. Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients. Arch Surg. 2008;143:463–470.
   PubMedGoogle Scholar
• Sodha NR, Clements RT, Boodhwani M, et al. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol. 2009;296:H428–H434.
   PubMed Web of Science ®Google Scholar
• Matyal R, Mahmood F, Robich M, et al. Chronic type II diabetes mellitus leads to changes in neuropeptide Y receptor expression and distribution in human myocardial tissue. Eur J Pharmacol. 2011;665:19–28.
   PubMed Web of Science ®Google Scholar
• Carlsson AC, Ruge T, Sundstrom J, et al. Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage. Hypertension 2013;62:1146–1151.
   PubMed Web of Science ®Google Scholar
• Kawamoto KR, Davis MB, Duvernoy CS. Acute coronary syndromes: differences in men and women. Curr Atheroscler Rep. 2016;18:73.
   PubMed Web of Science ®Google Scholar
• Almgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens. 2007;25:1311–1317.
   PubMed Web of Science ®Google Scholar